Industry / Brazil

Tribunal Rules End Of Exclusivity For Pfizer's Lipitor

August 2010 | Industry Trend Analysis

Printable version
Bookmark

BMI View: Due to first-mover advantage, EMS is set to dominate the generic atorvastatin market, while Pfizer's partner Eurofarma awaits regulatory approval.

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles

Clinical Diagnostics Firm Acquisition Enthuses Investors

Industry / Brazil BMI View: Increasing levels of investment in the public sector, as well as the expansion of private healthcare over the past decade due to growing demand from a booming middle-class, have resulted in increased...

December 2010

Droga Raia's Expansion Plans

Industry / Brazil BMI View: While the fragmented nature of the Brazilian pharmacy retail market offers pharmacy chains opportunities for growth through consolidation, we believe over-consolidation may result in increased...

December 2010

Tailored Strategies Required For Expansion In A Complex Pharmaceutical Market

Industry / Brazil BMI View: Drugmakers cannot afford to ignore the impressive long-term potential of Brazil's pharmaceutical industry. However, innovative drugmakers are likely to face significant challenges given that...

November 2010

Aché Enters Mexican Anti-Hypertensive Drug Market Through Partnership With Local Firm

Industry / Brazil BMI View: Partnering with local pharmaceutical firms will become increasingly important for companies expanding in Latin America. New entrants to emerging markets will minimise risks by partnering with...

November 2010

Pfizer Signs Teuto And Biocon Deals

Industry / Brazil BMI View: With a number of blockbuster drugs expected to lose patent protection by 2015, Pfizer's aggressive expansion efforts - in the generic and biosimilar drug market segments of high-growth emerging...

October 2010